Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab

BACKGROUND: Nivolumab is an anti-PD1 checkpoint inhibitor active in patients with advanced melanoma and as adjuvant therapy in high-risk metastatic melanoma patients. METHODS: In this single-center retrospective analysis, we investigated the CD73 enzyme activity in patients with metastatic melanoma...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Transl Med
Main Authors: Morello, Silvana, Capone, Mariaelena, Sorrentino, Claudia, Giannarelli, Diana, Madonna, Gabriele, Mallardo, Domenico, Grimaldi, Antonio M., Pinto, Aldo, Ascierto, Paolo Antonio
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5716054/
https://ncbi.nlm.nih.gov/pubmed/29202855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-017-1348-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados